Clinical Trial Update: ASP8374 + Cemiplimab in Recurrent Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ASP8374 in combination with cemiplimab for recurrent glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• ASP8374
• Cemiplimab (cemiplimab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Glioblastoma, Recurrent Glioblastoma | Phase 1 | Status: COMPLETED